title: Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).
authors.affiliation: Institute of Hematology, Western Galilee Hospital, Nahariya, Israel. andrei.braester@naharia.health.gov.il
authors.forename: A
authors.initials: A
authors.lastname: Braester
authors.forename: L
authors.initials: L
authors.lastname: Akria
authors.forename: C
authors.initials: C
authors.lastname: Suriu
authors.forename: V
authors.initials: V
authors.lastname: Sonkin
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab